22.58  0 (0%)		12-31 19:00
Open: 22.56 High: 22.59 Volume: 1,347,169		Pre. Close: 22.58 Low: 22.56 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	26.38	1-year :	30.81
Resists	First :	22.59	Second :	26.38
Pivot price	22.57
Supports	First :	22.57	Second :	22.55
MAs	MA(5) :	22.57	MA(20) :	22.57
	MA(100) :	21.42	MA(250) :	20.42
MACD	MACD :	0	Signal :	0.1
%K %D	K(14,3) :	66.6	D(3) :	66.6
RSI	RSI(14): 75.6
52-week	High :	22.6	Low :	10.81

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SOLY ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas. As of December 16, 2021, Soliton, Inc. operates as a subsidiary of Allergan plc.

Mon, 10 May 2021
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio - PR Newswire

Wed, 05 May 2021
Introducing RESONIC™ - PR Newswire

Sun, 21 Feb 2021
Soliton: Slow, Steady Progress Could Win Tattoo & Cellulite Removal Race (NASDAQ:SOLY) - Seeking Alpha

Thu, 22 Oct 2020
Soliton Appoints Niquette Hunt to Board of Directors - BioSpace

Thu, 13 Aug 2020
Soliton Introduces Advanced Design for RAP Cartridges - BioSpace

Mon, 17 Feb 2020
Soliton: A Solid Play On The Tattoo Removal Opportunity In 2020 (NASDAQ:SOLY-DEFUNCT-598190) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	22 (M)
Held by Insiders	9.84e+006 (%)
Held by Institutions	46.5 (%)
Shares Short	1,740 (K)
Shares Short P.Month	0 (K)

EPS	-2.321e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-6 %
Return on Assets (ttm)	421.3 %
Return on Equity (ttm)	-47.6 %
Qtrly Rev. Growth	370000 %
Gross Profit (p.s.)	0
Sales Per Share	-355.39
EBITDA (p.s.)	0
Qtrly Earnings Growth	-0.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-17 (M)

PE Ratio	-0.01
PEG Ratio	-0.6
Price to Book value	0
Price to Sales	-0.07
Price to Cash Flow	4.1

Dividend	0
Forward Dividend	1.63e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.